Two patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2036. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2036
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2019 to 2036.20232027203120352036
9 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Sep 2036 · High confidence
Also notable
Ends Sep 2036 · High confidence
A Combination Therapy Comprising Varlitinib and an Anticancer Agent
US 10,357,494
Granted 2019. Computed term ends 2036.
Varlitinib for Use in the Treatment of Resistant or Refractory Cancer
US 10,682,353
Granted 2020. Computed term ends 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for A Combination Therapy Comprising Varlitinib and an Anticancer Agent (US 10,357,494) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| A Combination Therapy Comprising Varlitinib and an Anticancer Agent | 1 in force | to Sep 2036 |
| Varlitinib for Use in the Treatment of Resistant or Refractory Cancer | 1 in force | to Sep 2036 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,357,494 | A Combination Therapy Comprising Varlitinib and an Anticancer Agent In force · High confidence | In force | High confidence | |
| US 10,682,353 | Varlitinib for Use in the Treatment of Resistant or Refractory Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 3 patents ended · 9 applications pending · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.